0 items
Your cart is empty.
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
$38.00
this product is available by prescription only
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
The 10mg vial provides the highest available GLP-1 receptor agonist concentration for institutional research use, accommodating comprehensive dose escalation designs — from low baseline concentration through maintenance-level dosing ranges — within a single vial. This format supports multiple concurrent protocol arms, reduces logistical interruption between experimental phases, and simplifies peptide inventory management for professional laboratories managing large-scale or multi-site research programs.
Semaglutide’s C18 fatty diacid chain modification enables albumin binding and extends plasma half-life to approximately one week, supporting once-weekly preclinical administration schedules and stable GLP-1 receptor occupancy across extended observation windows. This pharmacokinetic profile is particularly relevant for multi-week longitudinal protocols where consistent receptor exposure is required to characterize cumulative downstream cAMP signaling pathway marker changes and metabolic endpoint progression systematically over time — without the dosing frequency variability associated with shorter-acting GLP-1 receptor agonist reference compounds.
GLP-1 receptor activation by Semaglutide initiates Gs-protein-coupled adenylyl cyclase activity, elevating intracellular cAMP concentrations and driving PKA-dependent phosphorylation cascade dynamics in GLP-1 receptor-expressing pancreatic beta-cell, hypothalamic, and cardiovascular cell populations. Downstream molecular endpoints — including insulin secretion assay output, glucagon suppression pathway marker expression, and glucose transporter regulatory marker activity — represent the primary signaling parameters quantified in GLP-1 receptor pharmacology and incretin pathway research designs using Semaglutide as a long-acting reference agonist.
Novera supplies Semaglutide 10mg sourced from USA GMP-certified manufacturing facilities, independently verified to greater than 99% purity by HPLC and third-party COA documentation. Each vial confirms complete peptide sequence identity, purity grade, and batch-specific quality control data — providing institutional laboratories with consistent, pharmaceutical-grade GLP-1 receptor agonist material for advanced large-scale incretin signaling research.
Semaglutide 10mg is suited for institutional and professional research laboratories requiring maximum peptide concentration for large-scale GLP-1 receptor pharmacology programs, multi-arm metabolic signaling endpoint studies, and extended dose escalation protocol designs. Research teams conducting high-volume preclinical investigations of GLP-1 receptor binding kinetics, incretin-mediated cAMP pathway dynamics, or longitudinal insulin secretion and glucagon suppression pathway marker characterization benefit from this concentration’s capacity to support multiple concurrent study arms within a single procurement cycle. Laboratories managing 52–104 week extended observation programs benefit from the reduced vial turnover and simplified inventory management this maximum-concentration format provides. Novera supplies Semaglutide 10mg sourced from USA GMP-certified manufacturing facilities, with each vial COA-verified for greater than 99% purity and sequence identity.
Semaglutide 10mg supports high-volume in-vitro investigation of GLP-1 receptor binding kinetics, receptor occupancy dynamics, and downstream cAMP second messenger pathway activity across multiple concurrent experimental arms in pancreatic beta-cell line and primary culture model systems. Researchers characterizing long-acting GLP-1 analog receptor interaction profiles, dose-dependent binding affinity parameters, and receptor subtype selectivity dynamics use this concentration to support comprehensive multi-arm receptor pharmacology study designs efficiently within a single procurement cycle.
The 10mg vial accommodates full systematic dose escalation study designs — from 0.25mg baseline through 0.5mg, 1mg, 1.7mg, and 2.4mg experimental stages — within a single vial, enabling comprehensive coverage of concentration-dependent receptor pathway activation kinetics and signaling cascade dynamics without logistical interruption between escalation phases. This supports thorough characterization of dose-response relationship dynamics and threshold signaling marker activity across the full experimental concentration range.
Institutional laboratories conducting simultaneous multi-arm investigations of GLP-1 receptor-mediated metabolic signaling endpoints use the 10mg concentration to support parallel quantification of insulin secretion assay output, glucagon suppression pathway marker expression, cAMP-PKA phosphorylation cascade dynamics, and glucose transporter regulatory marker activity across multiple experimental conditions within the same study design. Multi-arm comparative protocols examining GLP-1 receptor agonist concentration-dependent effects on these endpoints benefit from the logistical simplicity this format provides.
The 10mg concentration supports 52–104 week extended longitudinal research programs examining cumulative GLP-1 receptor pathway marker progression, long-term receptor activity dynamics, and multi-phase dose escalation response characterization in preclinical metabolic model systems. Professional laboratories managing multi-year institutional research programs benefit from the operational efficiency this maximum-concentration format provides, supporting consistent peptide availability and reproducible molecular endpoint datasets across all extended protocol phases.
Reconstitute lyophilized Semaglutide 10mg with sterile bacteriostatic water using strict aseptic technique under standard sterile laboratory conditions. Reconstitution volume should be determined based on the target experimental working concentration and dose escalation stage specified by the study design. Laboratory protocols commonly escalate from 0.25mg baseline through successive concentration stages; document each reconstitution step in accordance with institutional research record-keeping standards. Use calibrated laboratory equipment throughout all preparation steps.
Store lyophilized peptide at 2–8°C, protected from light and moisture, prior to reconstitution. Following reconstitution, maintain refrigeration at 2–8°C; reconstituted peptide is typically stable for 2–4 weeks under appropriate storage conditions. This product does not require cold-chain shipping, but immediate refrigeration upon receipt is recommended to preserve peptide integrity throughout the protocol period. Each vial supplied by Novera includes COA documentation and detailed handling instructions.
Extended institutional metabolic signaling research protocols using Semaglutide 10mg typically span 52–104 weeks for comprehensive longitudinal GLP-1 receptor characterization and metabolic pathway marker progression observation. Systematic dose escalation designs allow characterization of receptor pathway activation threshold dynamics and concentration-dependent signaling endpoint differences across the full experimental range. Monitor GLP-1 receptor pathway activity markers, insulin secretion assay endpoints, glucagon suppression pathway expression, and downstream metabolic signaling markers at defined experimental intervals throughout the observation period.
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
High-purity, research-grade peptide synthesis
Analytical testing to verify quality and composition
Consistent batch-to-batch performance
Batch identification on every vial for traceability
Stored and shipped under controlled conditions
Research-grade dual-peptide blend combining short-acting synthetic peptides for flexible laboratory research protocols.
Research-grade synthetic thymic peptide formulated in 10mg quantity for immune peptide studies and thymosin mechanism research in controlled laboratory environments.
Research-grade selective synthetic pentapeptide formulated for experimental peptide interaction research in controlled laboratory settings.
High-purity research peptide supplied for controlled laboratory studies. B7-33 (5mg) is a precisely characterized peptide fragment. Its structural definition and batch consistency make it a reliable choice for laboratories performing...
Research-grade cathelicidin-derived peptide formulated for experimental immune-related research in controlled laboratory environments.
